Clinical Trial Detail

NCT ID NCT03511222
Title Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

stomach cancer

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

Advanced Solid Tumor

Therapies

Pembrolizumab + Vorolanib

Nivolumab + Vorolanib

Age Groups: adult senior

No variant requirements are available.